Tennessee Abbott Baby Formula Settlement: State Recovers $2.3M

• Tennessee will recover $2,349,346.04 from a $384.9 million multistate and federal settlement with Abbott Laboratories.
• The settlement resolves allegations that Abbott submitted false claims to federal and state programs due to failed safety standards for infant formula and nutritional products.
• Abbott's alleged failures between 2018 and 2022 included poor equipment maintenance, inadequate contamination control, and non-disclosure of test results at its Michigan and Arizona facilities.
• The resolution stems from a `qui tam` lawsuit and subsequent complaints alleging violations of federal and state False Claims Acts.
• The settlement underscores the importance of manufacturers adhering to strict safety and quality control standards, especially for products supplied to vulnerable populations through government programs.

Parents in Tennessee must have absolute certainty regarding the safety of the food they provide for their infants.

Tennessee is set to receive over $2.3 million as part of a significant $384.9 million multistate and federal resolution with Abbott Laboratories. This comprehensive settlement addresses allegations concerning the failure to uphold safety standards in the production of powdered infant formula and various nutritional therapy products. The agreement resolves claims that Abbott caused the submission of false claims to both federal and state programs, including Medicaid and WIC, by not manufacturing certain products in adherence to required safety protocols.

Attorney General Jonathan Skrmetti announced Tennessee's recovery of $2,349,346.04 from the overall settlement. This outcome stems from a collaborative effort involving Tennessee, 39 other states, and the federal government, all united in holding the manufacturer accountable for its alleged shortcomings. The financial penalties are substantial, with Abbott Laboratories agreeing to pay $348,700,868 to the United States and an additional $36,298,172 to the participating states for claims tied to their respective Medicaid and WIC programs, which provide crucial nutritional support to eligible families.

The core of the allegations against Abbott Laboratories centers on manufacturing deficiencies identified between January 1, 2018, and December 31, 2022. During this period, at its facilities located in Sturgis, Michigan, and Casa Grande, Arizona, Abbott allegedly failed to properly maintain manufacturing equipment. Furthermore, the company was accused of not adequately controlling conditions that could elevate the risk of microorganism contamination in its products.

Adding to these concerns, the settlement addresses instances where Abbott reportedly did not disclose test results indicating contamination during inspections conducted by the Food and Drug Administration (FDA). These alleged failures directly impacted the integrity and safety of infant formula and nutritional products, raising serious questions about product quality control and compliance with established safety standards for regulated goods.

This significant resolution, often referred to as the Tennessee Abbott baby formula settlement in the context of state-specific recoveries, originated from a `qui tam` lawsuit filed in 2022 within the U.S. District Court for the Western District of Michigan. Following this initial action, the United States and numerous states, including Tennessee, subsequently filed their own complaints. These complaints specifically alleged violations of both federal and state False Claims Acts, asserting that Abbott's manufacturing failures led to fraudulent claims being submitted to government-funded health and nutrition programs.

The investigation and subsequent settlement negotiations were a complex, coordinated effort. A dedicated team from the National Association of Medicaid Fraud Control Units (NAMFCU) played a pivotal role on behalf of the states. This team comprised representatives from the Offices of the Attorneys General for several states, including California, Connecticut, Colorado, Florida, Maryland, Massachusetts, Michigan, New York, Ohio, Oregon, and Tennessee, underscoring the broad impact and collaborative nature of this multistate infant formula settlement.

The outcome of this case highlights the critical importance of stringent quality control and compliance programs for manufacturers of regulated products, particularly those supplying government initiatives like Medicaid and WIC. The allegations of `Medicaid WIC fraud Abbott` and the subsequent settlement serve as a stark reminder of the severe penalties that can arise from failing to meet safety standards and accurately report to federal and state agencies. For manufacturers, this underscores the necessity of strengthening internal compliance to mitigate exposure under the False Claims Act.

Attorney General Jonathan Skrmetti emphasized the public trust involved, stating that parents in Tennessee must have absolute certainty regarding the safety of the food they provide for their infants. He affirmed the commitment to holding manufacturers accountable when they fail to meet legal and parental expectations. This `baby formula safety standards lawsuit` and its resolution reinforce the principle that companies selling baby food in Tennessee, and across the nation, are expected to rigorously adhere to all applicable rules and regulations, ensuring the well-being of vulnerable consumers.

Manufacturers of regulated products, particularly those supplying government programs, must review and strengthen their quality control and compliance programs to mitigate False Claims Act exposure. This settlement underscores the severe penalties for failing to meet safety standards and accurately report to federal and state agencies.

Source: Original reporting via Tennessee Attorney General's Office